Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on May 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events). Up to 6,455,778 shares issuable upon note conversion, creating potential shareholder dilution.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Up to 6,455,778 shares issuable upon note conversion, creating potential shareholder dilution
- Initial conversion rate of 9.3562 shares per $1,000 principal, subject to customary anti-dilution adjustments
- 3,220,529 common shares issued in note exchange transactions under Section 4(a)(2) exemption
- Notes and potential conversion shares unregistered, limiting resale absent registration or an exemption
Item 8.01 · Other Events
- Mirum launched and priced a Notes offering on May 12, 2026
- Debt financing creates potential interest and repayment obligations for the company
- Use of proceeds and pricing terms are in Exhibits 99.1 and 99.2
- Investor focus: leverage impact and whether proceeds support growth or liquidity needs
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.